Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
Phase 2
Active, not recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Ozurdex® Ophthalmic Intravitreal ImplantDrug: OXU-001Device: Semi-automated suprachoroidal illuminated microcatheter
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Oxular Limited
- Target Recruit Count
- 3
- Registration Number
- NCT05697809
- Locations
- 🇵🇷
Emmanuelli Research and Development Center, LLC, Arecibo, Puerto Rico
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Blue Ocean Clinical Research West, Clearwater, Florida, United States
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Triamcinolone AcetonideDevice: Semi-automated Suprachoroidal Microcatheter
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Oxular Limited
- Target Recruit Count
- 25
- Registration Number
- NCT05512962
- Locations
- 🇺🇸
Retina Consultants of Texas - The Woodlands, Houston, Texas, United States
🇺🇸Retina Consultants of Texas - Bellaire, Houston, Texas, United States
🇺🇸California Retina Consultants, Bakersfield, California, United States
Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema
Not Applicable
Withdrawn
- Conditions
- Diabetic Macular Edema
- Interventions
- Device: Oxulumis® suprachoroidal microcatheterization administration of Triesence®
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Oxular Limited
- Registration Number
- NCT05172401
© Copyright 2025. All Rights Reserved by MedPath